Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Maximilian Schinke, Inga Promny, MD, Stefanie Hieke, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, PhD, Milena Pantic, PhD, Justus Duyster, MD, Ralph Wäsch, MD PhD, Martin Schuhmacher, PhD, Monika Engelhardt, MD

Blood (2015) 126 (23): 2091.

https://doi.org/10.1182/blood.V126.23.2091.2091

Published: 2015

Journal Articles

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Alexander Zober, MD, Mandy Möller, Sandra-Maria Dold, Gabriele Ihorst, PhD, Stefanie Hieke, PhD, Jochen Knaus, Milena Pantic, PhD, Barbara Deschler-Baier, MD, Stefan Knop, Hermann Einsele, Christian Langer, Lars-Olof Muegge, MD, Wolfram Poenisch, MD, Justus Duyster, MD PhD, Martin Schumacher, PhD, Ralph M. Waesch, MD PhD, Monika Engelhardt, MD PhD

Blood (2015) 126 (23): 5616.

https://doi.org/10.1182/blood.V126.23.5616.5616

Published: 2015

Journal Articles

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Anne-Saskia Domm, Stefanie Hieke, Gabriele Ihorst, Milena Pantic, Bernd Koch, Martina Kleber, MD, Johannes Waldschmidt, MD, Martin Schumacher, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2014) 124 (21): 733.

https://doi.org/10.1182/blood.V124.21.733.733

Published: 2014

Journal Articles

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Milena Pantic, Bernd Koch, Gabriele Ihorst, Ralph Waesch, MD, Philippe Moreau, MD, Martin Schumacher, Monika Engelhardt, MD

Blood (2013) 122 (21): 1745.

https://doi.org/10.1182/blood.V122.21.1745.1745

Published: 2013

Journal Articles

Drug-Drug Interactions in the Hematology and Oncology Department: A Real-Life Assessment of Frequency and Severity

Barbara Metzke, Martin J Hug, PhD, Geertje Fink, MD, Stefanie Hieke, Manfred Jung, PhD, Monika Engelhardt

Blood (2012) 120 (21): 4250.

https://doi.org/10.1182/blood.V120.21.4250.4250

Published: 2012

Journal Articles

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Martina Kleber, Stefanie Hieke, Bernd Koch, Gabriele Ihorst, Ralph Wäsch, Martin Schumacher, Monika Engelhardt

Blood (2012) 120 (21): 4982.

https://doi.org/10.1182/blood.V120.21.4982.4982

Published: 2012

Journal Articles

Systemic Antifungal Drugs in the Hematology and Oncology Setting: A Real-Life Analysis in Consecutive Leukemia Patients of Patterns of Usage and Associated Problems,

Barbara Metzke, Stefanie Hieke, Manfred Jung, PhD, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2011) 118 (21): 4198.

https://doi.org/10.1182/blood.V118.21.4198.4198

Published: 2011

Journal Articles

Use of Systemic Antifungal Agents In Patients with Acute Leukemia: a Prospective Analysis Covering Clinical Parameters, Side Effects, Drug Interactions and Costs

Barbara Metzke, Stefanie Hieke, Werner Neubauer, PhD, Hartmut Bertz, PhD, Klaus Kümmerer, PhD, Manfred Jung, PhD, Monika Engelhardt, PhD

Blood (2010) 116 (21): 2568.

https://doi.org/10.1182/blood.V116.21.2568.2568

Published: 2010

Journal Articles

Rituximab Plus Bendamustin (R-B) Treatment In Patients with Aggressive Large B-Cell Lymphoma (LBCL): Response and Tolerability - a Single Institution Experience

Julia Horn, Martina Kleber, Ulrike Kohlweyer, Stefanie Hieke, Regina Herzog, Annette Schmitt-Gräff, Monika Engelhardt

Blood (2010) 116 (21): 4900.

https://doi.org/10.1182/blood.V116.21.4900.4900

Published: 2010

NARROW

Conditional Survival Analysis of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way to Provide More Specifically Determined Prognosis

Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)

Importance and Determinants of Comorbidities, Functional Limitations and Multiple Myeloma (MM)-Specific Risk Factors: Further Development of an Improved and Weighted MM-Risk Score (Freiburg Comorbidity Index [FCI])

Individual Patient Data Of Conditional Survival Analysis In a Large Cohort Of 816 Multiple Myeloma (MM) Patients Constitutes a Different Way To Identify Patients With Extended Life Expectancy

Drug-Drug Interactions in the Hematology and Oncology Department: A Real-Life Assessment of Frequency and Severity

Conditional Survival Analysis in a Large Cohort of Multiple Myeloma Patients Provides Detailed Information about Long-Term Survival and Constitutes a Different Way to Identify Patients with Extended Life Expectancy

Systemic Antifungal Drugs in the Hematology and Oncology Setting: A Real-Life Analysis in Consecutive Leukemia Patients of Patterns of Usage and Associated Problems,

Use of Systemic Antifungal Agents In Patients with Acute Leukemia: a Prospective Analysis Covering Clinical Parameters, Side Effects, Drug Interactions and Costs

Rituximab Plus Bendamustin (R-B) Treatment In Patients with Aggressive Large B-Cell Lymphoma (LBCL): Response and Tolerability - a Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only